Clinical data | |
---|---|
Trade names | Veltassa |
Other names | RLY5016 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a616012 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (suspension) |
Drug class | Potassium binder[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Not absorbed |
Metabolism | None |
Onset of action | 7 hrs; 1-2 wks for max effect[1] |
Duration of action | 24 hrs |
Excretion | Feces |
Chemical and physical data | |
Formula | [(C3H3FO2)182·(C10H10)8·(C8H14)10]n [Ca91(C3H2FO2)182·(C10H10)8·(C8H14)10]n (calcium salt) |
Patiromer, sold under the brand name Veltassa, is a medication used to treat high blood potassium.[1] It is taken by mouth.[1] Its onset of action begins in about 7 hours, with maximum efforts taking a week or two.[1]
Common side effects include constipation, low blood magnesium, nausea, and abdominal pain.[1] Other side effects may include high calcium and intestinal perforation.[4] It works by binding potassium in the gut, increasing its loss in the stool.[2]
Patiromer was approved for medical use in the United States in 2015 and Europe in 2017.[1][3] In the United Kingdom it costs the NHS about £170 per month as of 2021.[4] This amount in the United States costs about 1,000 USD.[5]
References edit
- ^ a b c d e f g h i "Patiromer Sorbitex Calcium Monograph for Professionals". Drugs.com. February 2017. Archived from the original on 13 November 2019. Retrieved 13 November 2019.
- ^ a b c "Veltassa- patiromer powder, for suspension". DailyMed. 23 October 2019. Archived from the original on 20 October 2020. Retrieved 18 October 2020.
- ^ a b "Veltassa". Archived from the original on 21 October 2020. Retrieved 26 October 2021.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1105. ISBN 978-0857114105.
- ^ "Veltassa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 24 August 2019. Retrieved 26 October 2021.